Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema

被引:0
作者
Ahmed F. Gabr
Marian F. Kamel
Ahmed A. Elbarawy
机构
[1] Aswan University,Ophthalmology Department, Faculty of Medicine
来源
International Ophthalmology | 2023年 / 43卷
关键词
Diabetic macular edema; Ranibizumab; Bromfenac; Macular thickness; Intravitreal injection;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3219 / 3226
页数:7
相关论文
共 70 条
[1]  
Lee R(2015)Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss Eye Vis (Lond) 2 17-28
[2]  
Wong TY(2009)Pathophysiology of diabetic macular edema Int Ophthalmol Clin 49 1-11
[3]  
Sabanayagam C(2015)Diabetic macular edema. Rom J Ophthalmol 59 133-136
[4]  
Singh A(2006)Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 859-870
[5]  
Stewart JM(2012)Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration Retina 32 1804-1810
[6]  
Musat O(2000)Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers Inflammation 24 371-384
[7]  
Cernat C(2005)Serum inflammatory markers in diabetic retinopathy Invest Ophthalmol Vis Sci 46 4295-4301
[8]  
Labib M(2006)Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug Int Ophthalmol Clin 46 20-32
[9]  
Ferrara N(2008)Randomized, double- masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 239-248
[10]  
Damico L(2010)Complications of intravitreal injections Curr Opin Ophthalmol 21 178-183